Report Snapshot

Otsuka

• Otsuka’s revenue increased by 8.1% in 2019 compared to 2018 in local currency. Sales of four global products (Abilify Maintena, Rexulti, Samsca, Lonsurf) increased by 34.9%, contributing significantly to the revenue growth.
• Otsuka compares unfavourably to most peers over both near-term (2019-2024) and long-term (2024-2029) revenue growth rates; the company is expected to generate just over 8% of revenue from launch products in 2025, which is lower than peer average.
• Otsuka’s revenue will continue to be positively impacted by prescription and sales growth in its global products.
• One of the strategies that Otsuka will pursue for revenue growth in the medium term (2019–2023) is to maximize existing business value by investing in the growth of its four global products. However, the company is expecting patent expirations for these mainstay products in the long-term.
• Otsuka is expected to generate a significant amount of sales from central nervous system in the forecast period, followed by oncology and metabolic therapy areas.
• Otsuka has a global presence; however, it is expected to generate majority of its sales in Japan, followed by the US.
• Otsuka’s launch profile shows promise to continue sales growth to be able to offset losses from generic drugs.
• Rexulti is highly evaluated for its efficacy and safety as a new treatment option for major depressive disorder and schizophrenia in the US. Several clinical trials are under way with the aim of further contributing to treating unmet needs in the psychiatry and neurology area, which will further expand its market.
• Samsca is highly evaluated in various guidelines in Japan, and prescriptions are increasing for the treatment of cardiac edema, hepatic edema, and ADPKD.
• High-impact upcoming events comprise topline Phase III trial results for Rexulti and centanafadine as well as topline Phase II trial results for Rexulti.